All In Biotech

Drug Trial Radar · NCT07680946

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Dec 12, 2028

Study completion Mar 1, 2029

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • UblituximabDrug

    Administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with at Least 20% Reduction From Baseline in PANSS Total ScoreTime frame: At Week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Little Rock, Arkansas · Recruiting

  • TG Therapeutics Investigational Trial Site

    Richardson, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.